Savella treats a chronic pain disorder called fibromyalgia. Savella is the first drug the Food and Drug Administration has approved for the treatment of fibromyalgia. Savella works on the central nervous system to increase pain signal inhibitors in the body, namely norepinephrine (NE) and serotonin, which work in the spinal cord. Increasing these chemicals' effects ensure that fewer signals reach the brain and reduce the feeling of pain.
Savella is a medicine used in the treatment of fibromyalgia, a condition characterised by chronic pain in the muscles and joints. The active ingredient of Savella, milnacipran, belongs to an antidepressant class called SNRIs or serotonin-norepinephrine reuptake inhibitors.
In other words, Savella works to increase serotonin and norepinephrine between nerve terminals and neurotransmitters believed to play an important role in causing fibromyalgia. Though classified as an antidepressant, Savella itself is not used in the treatment of depression.
Savella is associated with a range of potential side effects. Among them include nausea, vomiting, constipation, headache, dizziness, sleep disturbances, high blood pressure, and flushing.